EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer

Amirsalar Mansouri iD, Olivia Hart iD, Sina Aslanabadi iD, Conner Hartupee, Dicle Yalcin iD, Garima Sinha iD, Chiswili Yves Chabu, Aleksandra Cios iD, Zetao Cheng, Sudhakar Ammanamanchi iD, Jovanny Zabaleta iD, John H Stewart und 5 weitere

Cells · 17.03.2026 · 15 (6) · 531

DOI: 10.3390/cells15060531 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cells, online erschienen am 17.03.2026. Verfasst von Amirsalar Mansouri und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interdisciplinary Oncology, Louisiana State University (LSU) Health School of Medicine-New Orleans, New Orleans, LA 70112, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proteomics, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Northern Cancer Institute, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a 5-year survival rate of 13.3%. First-line treatment relies on two chemotherapy regimens, FOLFIRINOX (FOLFNX) or gemcitabine plus nab-paclitaxel (GEMPAC). However, direct clinical comparisons between these regimens have yielded inconsistent results across survival and toxicity endpoints, and the molecular basis of heterogeneous treatment responses remains poorly defined. To investigate regimen-specific tumor-cell-intrinsic mechanisms, we performed quantitative proteomic profiling of a primary PDAC-derived MIA PaCa-2 cell line following treatment with FOLFNX or GEMPAC. Differentially expressed proteins were analyzed using Gene Ontology, KEGG, and Ingenuity Pathway Analysis to define pathway-level alterations, and findings were contextualized using TCGA transcriptomic data. Proteomic analyses revealed that FOLFNX and GEMPAC engage in distinct cytotoxic programs. FOLFNX predominantly suppressed ribosome biogenesis and mitochondrial translation, consistent with sustained metabolic and biosynthetic stress, whereas GEMPAC preferentially disrupted mitotic cytokinesis and phosphatidylinositol phosphate biosynthesis, consistent with mitotic failure. Integration with TCGA data showed that FOLFNX-altered proteins aligned with favorable prognostic expression signatures, whereas GEMPAC-associated proteins were enriched among adverse profiles, reflecting engagement of distinct tumor-intrinsic programs. Together, these findings provide mechanistic insight into differential chemotherapy responses and establish a foundation for proteomics-based biomarkers to guide personalized chemotherapy selection in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsProteomicsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalHumansCell Line, TumorGemcitabineDeoxycytidinePaclitaxelGene Expression Regulation, NeoplasticFluorouracilIrinotecanLeucovorinOxaliplatin

Stichwörter der Autor:innen

FOLFIRINOXMIA PaCa2PDACchemotherapygemcitabineproteomics

Substanzen

GemcitabineDeoxycytidinePaclitaxelfolfirinoxFluorouracilIrinotecanLeucovorinOxaliplatin

Autor:innen und Institutionen

  • Department of Interdisciplinary Oncology, Louisiana State University (LSU) Health School of Medicine-New Orleans, New Orleans, LA 70112, USA.
  • LSU-LCMC Health Cancer Center, New Orleans, LA 70112, USA.
  • Department of Internal Medicine, Tulane University, New Orleans, LA 70118, USA.
  • Division of Surgical Oncology, Department of Surgery, Louisiana State University (LSU) Health-New Orleans, New Orleans, LA 70112, USA.
  • Division of Biological Sciences, University of Missouri, Columbia, MO 65211, USA.
  • Marlene and Stewart Greenebaum NCI Comprehensive Cancer Center, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.

ORCID-Profile: Amirsalar Mansouri, Olivia Hart, Sina Aslanabadi, Dicle Yalcin, Garima Sinha, Aleksandra Cios, Sudhakar Ammanamanchi, Jovanny Zabaleta, Bolni Marius Nagalo, Jiri Adamec, Omeed Moaven

Förderung

  • NIGMS NIH HHS
  • Northern Cancer Institute
  • National Institute of Health
  • CCSG
  • NIGMS
  • National Institutes of Health
  • American Association for Cancer Research
  • NIH

Zitieren

APA

Mansouri, A., Hart, O., Aslanabadi, S., Hartupee, C., Yalcin, D., Sinha, G., Chabu, C. Y., Cios, A., Cheng, Z., Ammanamanchi, S., Zabaleta, J., Stewart, J. H., West, J. T., Borad, M. J., Nagalo, B. M., Adamec, J., & Moaven, O. (2026). Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. Cells, 15(6), 531. https://doi.org/10.3390/cells15060531

Vancouver

Mansouri A, Hart O, Aslanabadi S, Hartupee C, Yalcin D, Sinha G, et al. Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. Cells. 2026;15(6):531. doi:10.3390/cells15060531

BibTeX
@article{Mansouri2026,
  author = {Mansouri, Amirsalar and Hart, Olivia and Aslanabadi, Sina and Hartupee, Conner and Yalcin, Dicle and Sinha, Garima and Chabu, Chiswili Yves and Cios, Aleksandra and Cheng, Zetao and Ammanamanchi, Sudhakar and Zabaleta, Jovanny and Stewart, John H and West, John T and Borad, Mitesh J and Nagalo, Bolni Marius and Adamec, Jiri and Moaven, Omeed},
  title = {Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {6},
  pages = {531},
  doi = {10.3390/cells15060531}
}
Kostenlos starten →